ENABLE-2

ENABLE-2 is an antibacterial drug discovery platform focused on the early stages of antibiotic discovery, supporting the development of direct-acting antibacterial compounds for systemic treatments. ENABLE-2 is based on learnings from ENABLE (Innovative Medicines Initiative) and is supported by the Swedish Research Council and the National Research Programme on Antibiotic Resistance. The ENABLE-2 platform is coordinated by Uppsala University and funded by the Swedish Research Council, the National Research Programme on Antibiotic Resistance. Researchers at publicly funded universities or research institutes in Europe (including non-EU countries such as UK, Norway, Switzerland, etc.) are eligible to apply. Please see our website for more information about ongoing programmes and how to apply: https://www.uu.se/en/department/medicinal-chemistry/enable2 ENABLE-2 platform partners Uppsala University (SE) SciLifeLab DDD (SE) Research Institutes of Sweden, RISE (SE) Statens Serum Institut (DK) Latvian Institute of Organic Synthesis (LV)